α5-GABA Receptor Inverse Agonists for Cognitive Deficits
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cognitive deficits associated with age-related diseases, neurodegenerative disorders, and schizophrenia have limited efficacy and are plagued by adverse effects, with existing benzodiazepine derivatives showing proconvulsant and anxiogenic adverse effects, necessitating the development of more effective and tolerable therapies that target specific GABA A receptor subunits.
Innovation Solution
Development of new 1,9-dihydro-2H-[1,3]oxazolo[4,5-h][2,3]benzodiazepin-2-one derivatives that selectively bind to the α5 subunit of the GABA A receptor, reducing GABA's effects, thereby offering a potential treatment for cognitive deficits and psychiatric disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective benzodiazepine agonists are used to treat cognitive deficits, then sedative, hypnotic, anxiolytic, anticonvulsant, amnesic, anti-nociceptive and muscle relaxant effects are produced, but proconvulsant and anxiogenic adverse effects occur
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (formula I) that selectively target the α5 subunit of GABA A receptors. This selective binding property ensures that therapeutic effects are produced at the specific receptor subtype responsible for cognitive functions, while avoiding activation of other subunit combinations that mediate adverse effects.
Solution Approach 2:
The invention segments the GABA A receptor target into specific subunit types (α5-containing receptors) rather than acting on all GABA A receptors non-selectively. By developing compounds that specifically bind to α5 subunits, the patent isolates the therapeutic action to a particular receptor segment, thereby achieving cognitive benefits without the harmful effects associated with broader receptor activation.
2Reliability
If existing treatments (cholinesterase inhibitors or memantine) are used for Alzheimer's disease, then some therapeutic effect is achieved, but adverse effects are numerous or effectiveness is limited
Solution Approach 1:
The patent changes the pharmacological parameter from non-selective enzyme inhibition or NMDA antagonism to selective α5-GABA A receptor modulation. This parameter change involves developing compounds with specific molecular structures (formula I) that bind selectively to α5-containing receptors, offering a different mechanism of action that may provide improved therapeutic effectiveness with reduced adverse effects.
3Reliability
If inverse agonists are used to treat cognitive disorders, then beneficial procognitive activity is produced, but proconvulsant and anxiogenic adverse effects prevent further clinical studies
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (formula I) that selectively target the α5 subunit of GABA A receptors. This selective binding property ensures that therapeutic effects are produced at the specific receptor subtype responsible for cognitive functions, while avoiding activation of other subunit combinations that mediate adverse effects.
Solution Approach 2:
The invention inverts the approach by using inverse agonism specifically at α5-containing GABA A receptors rather than non-selective inverse agonism. This inverted strategy maintains the procognitive benefits observed with inverse agonists while selectively avoiding the proconvulsant and anxiogenic effects that occur with broader receptor inhibition.
Data Source
AI summary
Compounds of formula (I): in which: ➢ R1 represents a hydrogen atom or an alkyl group; ➢ R2 represents an alkyl group; ➢ R3 represents an aryl or heteroaryl group;